{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:39:14Z","timestamp":1792723154996,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.biopha.2020.110982","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T21:37:30Z","timestamp":1604525850000},"page":"110982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-6025","authenticated-orcid":false,"given":"Mina T.","family":"Kelleni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110982_bib0005","first-page":"1","article-title":"A contemporary review on pathogenesis and immunity of COVID-19 infection","author":"Mirzaei","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2020.110982_bib0010","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"issue":"10223","key":"10.1016\/j.biopha.2020.110982_bib0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.biopha.2020.110982_bib0020","first-page":"21","article-title":"Mechanisms of lymphocyte loss in SARS coronavirus infection","volume":"14","author":"Chan","year":"2008","journal-title":"Hong Kong Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2020.110982_bib0025","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2020.110982_bib0030","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2020.110982_bib0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2362.2004.01347.x","article-title":"Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol","volume":"34","author":"Panesar","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"issue":"1-2","key":"10.1016\/j.biopha.2020.110982_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.biopha.2020.110982_bib0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110982_bib0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.biopha.2020.110982_bib0055","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","author":"Pedersen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2020.110982_bib0060","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2020.110982_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110982_bib0070","series-title":"Ibuprofen potential addition to COVID-19 early management protocols: could it be superior to paracetamol and hydroxychloroquine?","year":"2020"},{"key":"10.1016\/j.biopha.2020.110982_bib0075","series-title":"Multisystem Inflammatory Syndrome in Children and Adolescents Temporally Related to COVID-19","year":"2020"},{"key":"10.1016\/j.biopha.2020.110982_bib0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. Children and adolescents","author":"Feldstein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110982_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2020.110982_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","volume":"178","author":"Sallard","year":"2020","journal-title":"Antiviral Res."},{"issue":"214","key":"10.1016\/j.biopha.2020.110982_bib0095","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biopha.2020.110982_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2012.6936","article-title":"Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial","volume":"308","author":"Paton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110982_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","author":"Magagnoli","year":"2020","journal-title":"Med"},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.biopha.2020.110982_bib0120","series-title":"Hydroxychloroquine and COVID-19","author":"Q&A","year":"2020"},{"key":"10.1016\/j.biopha.2020.110982_bib0125","series-title":"\u201cSolidarity\u201d Clinical Trial for COVID-19 Treatments","year":"2020"},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-88-4-564","article-title":"Corticosteroid-induced Lymphopenia, immunosuppression, and body defense","volume":"88","author":"Craddock","year":"1978","journal-title":"Ann. Intern. Med."},{"issue":"4 Suppl","key":"10.1016\/j.biopha.2020.110982_bib0135","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1097\/01.CCM.0000057900.19201.55","article-title":"Glucocorticoids and acute lung injury","volume":"31","author":"Thompson","year":"2003","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110982_bib0140","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05073-9","article-title":"Rheumatologists\u2019 perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets","author":"Misra","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.biopha.2020.110982_bib0145","series-title":"Recommendations of Experts Relating to the Care in Resuscitation of SARS-CoV2 Epidemic Patients","year":"2020"},{"key":"10.1016\/j.biopha.2020.110982_bib0150","article-title":"Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary report","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110982_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106077","article-title":"Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study","author":"Bani-Sadr","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.biopha.2020.110982_bib0160","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/22221751.2020.1807885","article-title":"Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study","volume":"9","author":"Li","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"13","key":"10.1016\/j.biopha.2020.110982_bib0165","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and Ventilator-Free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.biopha.2020.110982_bib0170","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"The WHOREAfC-TWG","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110982_bib0175","first-page":"1","article-title":"Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All","author":"Waterer","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.biopha.2020.110982_bib0180","doi-asserted-by":"crossref","first-page":"985495","DOI":"10.5402\/2012\/985495","article-title":"Applications of steroid in clinical practice: a review","volume":"2012","author":"Shaikh","year":"2012","journal-title":"ISRN Anesthesiol."},{"key":"10.1016\/j.biopha.2020.110982_bib0185","series-title":"Breakthrough: Ibuprofen\/nitazoxanide\/azithromycin: a Battle Changer Personalized COVID-19 Telemedicine Five Days Protocol","year":"2020"},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0190","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.biopha.2020.110982_bib0195","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10787-020-00755-x","article-title":"ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror","volume":"28","author":"Kelleni","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"7","key":"10.1016\/j.biopha.2020.110982_bib0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40264-020-00953-0","article-title":"Does Ibuprofen Worsen COVID-19?","volume":"43","author":"Moore","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2020.110982_bib0205","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-020-00745-z","article-title":"Shah N: a narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality","author":"Smart","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"2004","key":"10.1016\/j.biopha.2020.110982_bib0210","first-page":"2007","article-title":"Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust","volume":"2020","author":"Bean","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2020.110982_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.03.040","article-title":"Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?","author":"Sodhi","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2020.110982_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.06.003","article-title":"Ibuprofen use and clinical outcomes in COVID-19 patients","author":"Rinott","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"9","key":"10.1016\/j.biopha.2020.110982_bib0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003308","article-title":"Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study","volume":"17","author":"Lund","year":"2020","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/194589240101500404","article-title":"The therapeutic effectiveness of ibuprofen on the symptoms of naturally acquired common colds","volume":"15","author":"Winther","year":"2001","journal-title":"Am. J. Rhinol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110982_bib0235","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1163\/156856003322699627","article-title":"Potential benefits of ibuprofen in the treatment of viral respiratory infections","volume":"11","author":"Winther","year":"2003","journal-title":"InflammoPharmacology"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220311744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220311744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:14:43Z","timestamp":1792721683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220311744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["S0753332220311744"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110982","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110982"}}